Volume 18, Number 10—October 2012
Dispatch
Human Parvovirus 4 in Nasal and Fecal Specimens from Children, Ghana
Table
Specimen type and no. | Nucleotide position according to GenBank accession no. EU874248 |
Nucleotide sequence divergence from parvovirus 4 reference strains, %
|
||
---|---|---|---|---|
Genotype 1 (GenBank AY622943) | Genotype 2 BR10627–5 (GenBank DQ873390) | Genotype 3 NG-OR (GenBank EU874248) | ||
Nasal swab | ||||
N1 |
1700–4660 | 6.56 | 7.39 | 0.92 |
N2 |
299–4660 | 7.51 | 8.07 | 0.88 |
N3 |
50–4660 | 7.37 | 8.38† | 0.83 |
N4 |
1962–2056‡ | 9.16 | 6.73 | 2.14 |
N4 |
2117–3413 | 4.97 | 5.31 | 0.93 |
N5 |
1962–2056 | 9.16 | 6.73 | 2.14 |
N5 |
2117–4183 | 5.50 | 6.34 | 0.98 |
N6 |
299–4660 | 7.51 | 8.10 | 0.90 |
N7 |
1962–2056 | 9.16 | 6.73 | 2.14 |
N7 |
2431–2914 | 6.24 | 7.01 | 1.25 |
N7 |
3068–3246 | 4.61 | 5.19 | 1.12 |
N8 |
624–3246 | 7.36 | 7.84 | 0.84 |
Feces | ||||
F1 |
1700–4183 | 6.20 | 6.82 | 0.89 |
F2 |
1700–4460 | 6.56 | 7.39 | 0.92 |
F3 |
1700–3716 | 6.08 | 6.52 | 0.85 |
F4 |
1700–4183 | 6.02 | 6.78 | 0.89 |
F5 |
1700–4183 | 6.93 | 6.73 | 1.04 |
*Pairwise nucleotide divergence was calculated by using the DNA distance matrix in BioEdit (www.mbio.ncsu.edu/BioEdit/bioedit.html).
†Because the homologs of the first 92 nt of strain N3 are not given in the prototype strain BR10627–5, calculation of divergence started at N3 nt position 93.
‡Nucleotide sequence of the PCR product (primer sequences trimmed) was amplified by using screening PCR designed for detection of PARV4 genotype 3 as described (7).
References
- Jones MS, Kapoor A, Lukashov VV, Simmonds P, Hecht F, Delwart E. New DNA viruses identified in patients with acute viral infection syndrome. J Virol. 2005;79:8230–6. DOIPubMedGoogle Scholar
- Fryer JF, Lucas SB, Padley D, Baylis SA. Parvoviruses PARV4/5 in hepatitis C virus–infected patient. Emerg Infect Dis. 2007;13:175–6. DOIPubMedGoogle Scholar
- Simmonds P, Manning A, Kenneil R, Carnie FW, Bell JE. Parenteral transmission of the novel human parvovirus PARV4. Emerg Infect Dis. 2007;13:1386–8. DOIPubMedGoogle Scholar
- Sharp CP, Lail A, Donfield S, Simmons R, Leen C, Klenerman P, High frequencies of exposure to the novel human parvovirus PARV4 in hemophiliacs and injection drug users, as detected by a serological assay for PARV4 antibodies. J Infect Dis. 2009;200:1119–25. DOIPubMedGoogle Scholar
- Lahtinen A, Kivela P, Hedman L, Kumar A, Kantele A, Lappalainen M, Serodiagnosis of primary infections with human parvovirus 4, Finland. Emerg Infect Dis. 2011;17:79–82. DOIPubMedGoogle Scholar
- Sharp CP, Vermeulen M, Nebie Y, Djoko CF, LeBreton M, Tamoufe U, Epidemiology of human parvovirus 4 infection in sub-Saharan Africa. Emerg Infect Dis. 2010;16:1605–7. DOIPubMedGoogle Scholar
- Panning M, Kobbe R, Vollbach S, Drexler JF, Adjei S, Adjei O, Novel human parvovirus 4 genotype 3 in infants, Ghana. Emerg Infect Dis. 2010;16:1143–6. DOIPubMedGoogle Scholar
- Yang SJ, Hung CC, Chang SY, Lee KL, Chen MY. Immunoglobulin G and M antibodies to human parvovirus 4 (PARV4) are frequently detected in patients with HIV-1 infection. J Clin Virol. 2011;51:64–7. DOIPubMedGoogle Scholar
- Benjamin LA, Lewthwaite P, Vasanthapuram R, Zhao G, Sharp C, Simmonds P, Human parvovirus 4 as potential cause of encephalitis in children, India. Emerg Infect Dis. 2011;17:1484–7.PubMedGoogle Scholar
- Yu X, Zhang J, Hong L, Wang L, Yuan Z, Zhang X, High prevalence of human parvovirus 4 infection in HBV and HCV infected individuals in Shanghai. PLoS ONE. 2012;7:e29474. DOIPubMedGoogle Scholar
- Lurcharchaiwong W, Chieochansin T, Payungporn S, Theamboonlers A, Poovorawan Y. Parvovirus 4 (PARV4) in serum of intravenous drug users and blood donors. Infection. 2008;36:488–91. DOIPubMedGoogle Scholar
- Simmonds P, Douglas J, Bestetti G, Longhi E, Antinori S, Parravicini C, A third genotype of the human parvovirus PARV4 in sub-Saharan Africa. J Gen Virol. 2008;89:2299–302. DOIPubMedGoogle Scholar
- Fryer JF, Delwart E, Hecht FM, Bernardin F, Jones MS, Shah N, Frequent detection of the parvoviruses, PARV4 and PARV5, in plasma from blood donors and symptomatic individuals. Transfusion. 2007;47:1054–61. DOIPubMedGoogle Scholar
- Sharp CP, Lail A, Donfield S, Gomperts ED, Simmonds P. Virologic and clinical features of primary infection with human parvovirus 4 in subjects with hemophilia: frequent transmission by virally inactivated clotting factor concentrates. Transfusion. 2012;52:1482–9. DOIPubMedGoogle Scholar
- Manning A, Russell V, Eastick K, Leadbetter GH, Hallam N, Templeton K, Epidemiological profile and clinical associations of human bocavirus and other human parvoviruses. J Infect Dis. 2006;194:1283–90. DOIPubMedGoogle Scholar
Page created: October 05, 2012
Page updated: October 05, 2012
Page reviewed: October 05, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.